Use of PLCO data to evaluate the performance of cancer risk models

Principal Investigator

Name
Thomas Ahearn

Degrees
PhD, MPH

Institution
Division of Cancer Genetics and Epidemiology, NCI

Position Title
Staff Scientisst

Email
thomas.ahearn@nih.gov

About this CDAS Project

Study
PLCO (Learn more about this study)

Project ID
PLCO-1025

Initial CDAS Request Approval
Aug 22, 2022

Title
Use of PLCO data to evaluate the performance of cancer risk models

Summary
In this project we will use PLCO data to evaluate the performance of cancer risk models. We will use data collected on the baseline questionnaire (BQ) to prospectively evaluate cancer risk models for: Breast, Lung and bronchus, Prostate, Colorectal, Melanoma of the skin, Urinary bladder, Non-Hodgkin lymphoma, Kidney and renal pelvis, Uterine corpus, Leukemia, Pancreas, Oral cavity and pharynx, Thyroid, Liver and intrahepatic bile duct, Myeloma.

In addition to the BQ data, we are also requesting that variables derived for the subset of PLCO study participants participating in the the collaboration with the Breast Cancer Association Consortium (BCAC) be derived for the rest of the PLCO study population.

Aims

We will use iCARE (PMID: 31165158) to evaluate the calibration and discrimination of cancer risk models (see list of cancers in Project Summary)

Collaborators

Montserrat Garcia-Closas (DCEG),
Nilanjan Chatterjee (Johns Hopkins University),
Parichoy Pal Choudhury (American Cancer Society),
Jeya Balasubramanian (DCEG),
Srijon Mukopadhyay (DCEG),
Jonas De Almedia (DCEG)